CLNN250117P7000
- 6.40
- 0.000.00%
Clene Newsroom
Clene Secures $10M Debt Facility to Enhance Position
Express News | Clene Improves Cash Position and Runway by Securing New Debt Facility to Pay off Existing Senior Loan
Press Release: Clene Improves Cash Position and Runway by Securing New Debt Facility to Pay Off Existing Senior Loan
Maxim Group Maintains Clene(CLNN.US) With Buy Rating, Maintains Target Price $20
Promising Prospects for Clene's ALS Treatment: Buy Recommendation Backed by Robust Data and Regulatory Progress
IBN Coverage: Clene (NASDAQ: CLNN) Advances CNM-Au8 in ALS With FDA Guidance on Accelerated Approval Pathway
Clene Gains FDA Support for ALS Treatment Approval
Clene Receives Written Guidance From DN1 of U.S. FDA on Pathway for CNM-Au8
Express News | Clene Inc. - Plans Nda Submission for ALS in Mid-2025
Express News | Clene Inc. - to Begin Phase 3 Restore-ALS Trial Before Nda Submission
Express News | Clene Inc. - FDA Recommends Follow-up Meeting for Accelerated Approval Pathway
Express News | Clene Inc. - FDA Recommends Clene Leverage Additional Nfl Data for ALS
Express News | FDA Provides Roadmap for Accelerated Approval Pathway Through Submission of Additional Cnm-AU8® Biomarker Data in ALS
FDA Provides Roadmap for Accelerated Approval Pathway Through Submission of Additional CNM-Au8 Biomarker Data in ALS
Benchmark Maintains Buy on Clene, Lowers Price Target to $84
Clene Price Target Maintained With a $23.00/Share by D. Boral Capital
Clene Is Maintained at Buy by D. Boral Capital
Express News | Clene Inc. Files for Offering of up to 2.4 Mln Shares of Common Stock by Selling Securityholders- SEC Filing
H.C. Wainwright Maintains Clene(CLNN.US) With Buy Rating, Maintains Target Price $31
Clene's Strategic and Financial Strengths Justify Buy Rating Amid Promising ALS Therapeutic Developments